Because adoptive transfer of naïve antigen-specific CD8+ T cells increases vaccine-elicited tumor immunity (Overwijk et al, 1998, 2003; Rizzuto et al, 2009), we coupled the MQ-treated tumor cell vaccine with adoptive transfer of naïve Pmel-1 TCR-transgenic gp100-specific CD8+ T cells (pmel) (Fig 1A). Here, CD8A is linked to neoplasm.